<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01259557</url>
  </required_header>
  <id_info>
    <org_study_id>MT-PRT-BP02</org_study_id>
    <nct_id>NCT01259557</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm</brief_title>
  <official_title>Multi-center, Phase Ⅳ, Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Meditoxin® in Subjects With Essential Blepharospasm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Meditoxin® in the
      treatment of Essential blepharospasm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change rate of Jankovic Rating Scale score</measure>
    <time_frame>4weeks</time_frame>
    <description>To evaluate the change of JRS(Jankovic Rating Scale) score at 4 weeks post treatment based on baseline( 0 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change rate of Jankovic Rating Scale scale</measure>
    <time_frame>0 week, 16weeks(or retreatment point)</time_frame>
    <description>To evaluate the change of JRS(Jankovic Rating Scale) at retreatment point or 16 weeks post treatment based on Baseline(0 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change rate of Blepharospasm Disability Index</measure>
    <time_frame>0week, 4weeks, 8weeks, 16weeks(or retreatment point)</time_frame>
    <description>To evaluate the change of Blepharospasm Disalbility Index at 4weeks, 8weeks, 16weeks(or retreatment point) post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment about the improvement</measure>
    <time_frame>4weeks</time_frame>
    <description>To evaluate the Global assessment about the improvement at 4weeks post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the duration of efficacy</measure>
    <time_frame>retreatment point or 16 weeks</time_frame>
    <description>To evaluate the duration of efficacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Essential Blepharospasm</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(Meditoxin®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>2 times, Intra-muscular injection, Maximum dosage total 60U</description>
    <arm_group_label>Botulinum toxin type A(Meditoxin®)</arm_group_label>
    <other_name>Meditoxin</other_name>
    <other_name>Neuronox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged above 18

          -  Subjects who was diagnosed with Essential Blepharospasm

          -  Subjects who voluntarily Signed written informed consent

          -  Subjects who can adhere to protocol and study requirements

        Exclusion Criteria:

          -  Subjects with known history of allergy considered due to Botulinum toxin type A

          -  Subjects who have received botulinum toxin A type within 3 months

          -  Any disease that might affect neuromuscular function (e.g.. Myasthenia Gravis,
             Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis ect.)

          -  Subjects who are participating in other clinical trials

          -  Pregnant or lactating female Subjects

          -  Subjects who are not eligible for the study at the discretion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaechan Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang university Yongsan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sevrance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang Univesity Yongsan Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>140-883</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2010</study_first_submitted>
  <study_first_submitted_qc>December 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2010</study_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <name_title>Yujin Sun / CRA</name_title>
    <organization>Medytox</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharospasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

